Dexamethasone phosphate otic solution

Phase 3

Alcon Research (ALC)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Acute Otitis Externa

View Full Landscape

Drug Information

Target Indication

Acute Otitis Externa

Clinical Trial

NCT00750633

Last updated: 12/31/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Dexamethasone Taw

Indicated for cerebral oedema, post-traumatic shock-lung syndrome, asthma, skin diseases, autoimmune diseases, rheumatoid arthritis, prophylaxis and treatment of post-operative or cytostatic-induced vomiting, treatment of COVID-19, eye inflammation and infection.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ALC

Alcon Research

Ophthalmic Goods•North America•NASDAQ

Related Pipeline

Ofloxacin otic solutionPhase 3

Acute Otitis Media

Difluprednate 0.05% ophthalmic emulsionPhase 3

Endogenous Anterior Uveitis